Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Subscribe To Our Newsletter & Stay Updated
